Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación y derecho · 11/12/20141 min de lectura
Prospective Grant of a Start-Up Exclusive Patent License Agreement: Use of Compounds Covered by Patent Rights for Diagnosis of Human Thyroid Cancer Requiring FDA Premarket Approval or an Equivalent Authority Outside of the United States, and Treatment of Human Thyroid Cancer
Traducción automática local · Idioma original de la fuente
Resumen
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to Nova Therapeutics LLC, a company having a place of business in Delaware, to practice the inventions embodied in the following patent applications:
Idioma original de la fuente: Federal Register — All DocumentsAbrir el comunicado original →